SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 1998
---------------------
Boston Scientific Corporation
(Exact name of registrant as specified in charter)
DELAWARE 1-11083 04-2695240
(State or other jurisdiction (Commission (IRS employer
of incorporation) file number) identification no.)
One Boston Scientific Place, Natick, Massachusetts 01760-1537
(Address of principal executive offices including zip code)
Registrant's telephone number, including area code: (508) 650-8000
<PAGE>
Item 5. Other Events
On September 10, 1998, Boston Scientific Corporation (the "Company")
announced that it had completed its acquisition of Schneider Worldwide, a member
of the Medical Technology Group of Pfizer Inc., for $2.1 billion in cash. The
purchase price was funded by the issuance of commercial paper.
The commercial paper issued will not be and has not been registered
under the Securities Act of 1933. Purchasers of the commercial paper may not
reoffer or resell it in the United States absent registration or an applicable
exemption from registration requirements.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits
Exhibit Number Description
-------------- -----------
99.1 Press Release dated September 10, 1998
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BOSTON SCIENTIFIC CORPORATION
Date: September 10, 1998 By:/s/ Lawrence J. Knopf
---------------------
Lawrence J. Knopf
Vice President and
Assistant General Counsel
<PAGE>
INDEX TO EXHIBITS
Exhibit Exhibit
Number Description Page
99.1 Press Release dated September 10, 1998 1
EXHIBIT 99.1
BOSTON SCIENTIFIC
ANNOUNCES COMPLETION OF
SCHNEIDER ACQUISITION
Natick, MA (September 10, 1998)--Boston Scientific Corporation
(NYSE:BSX) announced today that it has completed its acquisition of
Schneider Worldwide, a member of the Medical Technology Group of Pfizer
Inc. (NYSE:PFE), for $2.1 billion in cash. The purchase price was
funded by the issuance of commercial paper.
Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices. The Company's products are used in a broad range of
interventional medical specialties.
CONTACT: Larry Best (508-650-8450)
Sabrina Nicholson (508-647-2551)
Boston Scientific Corporation
The commercial paper will not be and has not been registered under the
Securities Act of 1933. Purchasers of the commerical paper may not
reoffer or resell it in the United States absent registration or an
applicable exemption from registration requirements.
